Key Documents

View All Documentation

D3900

Desipramine hydrochloride

Name: Desipramine hydrochloride
Brand: SIGMA

≥98% (TLC), powder, imipramine metabolite

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₈H₂₂N₂ · HCl

CAS Number:

58-28-6

Molecular Weight:

302.84

NACRES:

NA.77

PubChem Substance ID:

24278094

UNSPSC Code:

12352116

EC Number:

200-373-1

MDL number:

MFCD00058108

Assay:

≥98% (TLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Desipramine hydrochloride, ≥98% (TLC), powder

Quality Level

100

assay

≥98% (TLC)

form

powder

color

white to off-white

solubility

H₂O: 50 mg/mL

originator

Sanofi Aventis

storage temp.

2-8°C

SMILES string

Cl[H].CNCCCN1c2ccccc2CCc3ccccc13

InChI

1S/C18H22N2.ClH/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20;/h2-5,7-10,19H,6,11-14H2,1H3;1H

InChI key

XAEWZDYWZHIUCT-UHFFFAOYSA-N

Gene Information

human ... SLC6A2(6530)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

General description

Desipramine, a metabolite of imipramine and iofepramine is an active tricyclic antidepressant.

Application

Desipramine hydrochloride has been used:

to prevent norepinephrine neuron degeneration and to maximize uptake into DA neurons
to protect unselective damage to the noradrenergic system
as a norepinephrine re-uptake inhibitor to treat rats for lesioning

Biochem/physiol Actions

Desipramine is used to treat depression. It is also used to manage enuresis in children. Desipramine helps to eliminate the pain triggered by diabetic neuropathy.

Tricyclic antidepressant that is a more potent inhibitor of the norepinephrine transporter (K_i = 4 nM) than the serotonin transporter (K_i = 61 nM).

Features and Benefits

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Disclaimer

Hygroscopic

pictograms

GHS08,GHS07

signalword

Danger

hcodes

H302,H315,H317,H319,H334,H335

pcodes

P280 - P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Resonant antidromic cortical circuit activation as a consequence of high-frequency subthalamic deep-brain stimulation

Li S, et al.

Journal of Neurophysiology (2007)

Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy

Max M B, et al.

The New England Journal of Medicine, 326(19), 1250-1256 (1992)

Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease

Tillerson J L, et al.

Neuroscience, 119(3), 899-911 (2003)

Desipramine

reference module in biomedical sciences (2018)

Long-Term Treatment with Fluvoxamine Decreases Nonmotor Symptoms and Dopamine Depletion in a Postnatal Stress Rat Model of Parkinson's Disease.

Ernest Dallé et al.

Oxidative medicine and cellular longevity, 2020, 1941480-1941480 (2020-04-11)

Nonmotor symptoms (NMS) such as anxiety, depression, and cognitive deficits are frequently observed in Parkinson's disease (PD) and precede the onset of motor symptoms by years. We have recently explored the short-term effects of Fluvoxamine, a selective serotonin reuptake inhibitor

View All Related Papers

Global Trade Item Number

SKU	GTIN
D3900-1G	04061835253166
D3900-5G	04061833563694
D3900-25G	04061835253173

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service